IRS19 - instructions for use. IRS19 - instructions for use IRS 19 repeat course
Some facts about the product:
Instructions for use
Price in online pharmacy website: from 468
Pharmacological properties
The medical product IRS 19 is an immunostimulating drug that exhibits the properties of a local vaccine. Used for preventive therapy and treatment of diseases occurring in the upper respiratory tract and having an acute and chronic nature. The medicine is successfully used in the pediatric field.
The drug is included in the group of antibacterial vaccines due to lysates of strains of the most common pathogenic bacteria included in its composition. The production process of destroying microorganisms is carried out in such a way as to weaken the strains, but completely preserve their properties. When the active substance interacts with the immune system of the human body, specific and nonspecific protective immunity is developed. When carrying out the spraying procedure, a fine aerosol is formed that covers the mucous membranes of the nasal cavity, which contributes to the development of the immune response and forms specific protection. Specific protective functions are determined by the local formation of antibodies belonging to the class of secretory immunoglobulin, type A (IgA). Antibodies interfere with the processes of fixation and propagation of infection on the mucous membranes. The properties of nonspecific immune defense are an increase in phagocyte activity and an increase in lysozyme levels.
The drug has an almost instantaneous effect; after the first use, the duration of protection is about two hours. After a fourteen-day therapeutic course, the protective properties persist for three to four months. The medicine is well tolerated, which is why it is used in pediatric practice even in infants (from three months of age).
When using IRS 19 in complex treatment:
- The infectious-inflammatory process is inhibited at its very beginning.
- The duration of therapy with antibiotic and anti-inflammatory drugs is reduced.
- The healing process is accelerated.
- The risk of complications is reduced.
Indications for use
Indications for the use of the drug IRS 19 are the need for preventive therapy and treatment for the following diseases of the respiratory system and bronchial tree:
The drug is also used to restore the activity of local immunity after viral infections, including influenza.
In the preoperative and postoperative period during surgical interventions in the field of otolaryngology.
Contraindications
Contraindications to the use of the drug are:
- Hypersensitivity or individual intolerance to the components that are included in the structure of the product.
- Diseases that are associated with dysfunction of the immune system (autoimmune diseases).
Side effects
During therapy with the IRS 19 medication, the following negative manifestations may develop:
The immune system. In rare cases, allergic reactions may occur, manifested in redness of the skin, the development of erythema and eczema, and the occurrence of Quincke's edema.
Respiratory system. In rare cases, coughing and asthma attacks may develop.
Digestive system. There may be a feeling of nausea, vomiting, pain in the epigastric region, and disorders of the functions of the digestive system may also develop.
General. In rare cases, body temperature may rise sharply, and sinusitis, nasopharyngitis, laryngitis and bronchitis symptoms may develop.
If negative effects occur, it is necessary to interrupt therapy and seek advice from a specialist doctor, who, after an examination and additional research, will prescribe you a drug that is an analogue of the drug described.
Dosage and method of use
The drug is used intranasally (aerosol administration by pressing a spray bottle).
One short press is considered one dose.
During the procedure, you should keep the container with the medicine vertically.
For preventive therapy, adult patients and children over three months of age are recommended to start using the drug fourteen to twenty-one days before the expected period of general morbidity.
The dosage is to use one standard dose in each nostril twice a day.
The duration of the therapeutic course is fourteen days.
Treatment of diseases localized in the upper respiratory tract, acute and chronic in nature in patients over three years of age, is carried out using one standard dosage of the drug in each nostril, two to five times a day. For patients from three months to three years, the standard dosage is used twice a day.
The procedure is possible only after removal of mucous accumulations from the nasal cavity.
The therapeutic course is carried out until the manifestations of the infectious disease completely disappear.
To carry out procedures to restore local immunity after influenza and other infectious viral diseases in adult patients and children, it is necessary to carry out procedures using one standard dosage in each nostril twice a day.
The duration of the therapeutic course is fourteen days.
When carrying out preparatory measures before surgery, as well as for use in the postoperative period, it is necessary to use the product in one standard dosage in each nostril twice a day.
It is necessary to begin a therapeutic course of the drug seven days before a planned operation.
The duration of therapy is fourteen days.
In the first days of therapy, the following reactions may develop: increased sneezing and increased secretion of mucus from the nasal cavity. Most often these are short-term symptoms, however, if the described effects do not go away within the first few days of treatment, it is recommended to stop using the product and consult a specialist doctor for advice.
If the container with the medicine is not used for a long time, the opening of the nozzle may become clogged with crystallized substance. Most often, this can happen when removing the nozzle and placing it in a downward position with the upper end, without first rinsing and blowing. In order to avoid possible blockage, you should press the spray gun several times to create pressure that clears possible blockage. If this method is ineffective, you can immerse the nozzle in warm water for five to ten minutes to dissolve the crystals.
Overdose
Currently, there is no reliable information about the negative conditions of the patient during an overdose of the active substance. However, it can be assumed that when using a dosage exceeding the maximum therapeutic amount, the side effects described above may develop.
Features of use
The drug is intended for intranasal use; other methods of use are prohibited.
Before starting a therapeutic course, it is recommended to obtain an appropriate prescription from a specialist doctor and carefully read the instructions.
During the period of use of the product, it is necessary to comply with sanitary and hygienic standards for preparations of this type. Do not touch contaminated surfaces with the nozzle and store the product in special packaging. If necessary, the nozzle can be washed with warm water.
During the first days of therapy, increased secretion of mucus from the nose and increased sneezing may occur; this is considered a normal reaction and goes away after a few days. However, if symptoms persist, it is recommended to consult a doctor for advice.
Also, when using the drug, in very rare cases, an increase in body temperature is possible. If the temperature is significantly higher than normal, you should stop taking the drug and consult a doctor. However, it should be understood that an elevated temperature can also be caused by an infectious-inflammatory disease.
In case of development of bacterial infection, simultaneous use of the product with antibacterial drugs is possible.
If the patient has a history of bronchial asthmatic disease, an increased incidence of attacks may occur. In the case of such a course of the disease, it is recommended to interrupt the therapeutic course and not carry out procedures with similar drugs.
Before using the cylinder, it is necessary to center the nozzle and perform a control press.
The container with the drug should be kept vertical during the procedure.
It is forbidden to tilt your head back during the procedure.
With regular use of the product, the nozzle can be permanently on the bottle.
If there is a long break in use, the nozzle outlet may become clogged. In this case, you first need to press the spray gun several times in a row to create increased pressure, which will help clean the hole. If the above procedure does not produce an effect, it is recommended to immerse the nozzle in warm boiled water for five to ten minutes and then rinse it.
The container with the drug must be kept at room temperature. Do not heat or freeze the bottle, even if it is empty.
Do not damage the surface of the container.
Interaction with other drugs
If a bacterial infection develops, it is possible to use the product simultaneously with antibacterial drugs.
When combined with vasoconstrictor drugs used intranasally, it is necessary to interval between uses. It is recommended to carry out procedures with IRS 19 no earlier than thirty minutes after vasoconstrictor medications.
During clinical studies, no negative interactions with other drugs were identified
Use of the product during pregnancy and breastfeeding
Currently, there is no reliable information about clinical trials of the drug in women during pregnancy and the possible negative impact on the intrauterine development of the child and the health of the expectant mother.
There is no information about the possibility of penetration of the active substance into the secretion of the mammary glands. It is recommended to interrupt breastfeeding if there is a need to use the medication.
Driving vehicles and carrying out high-precision work
The drug does not have a negative effect on the psychomotor functions of the human body. There are no restrictions for driving vehicles or performing work that requires high concentration and attention during the therapy period.
Interaction with alcohol
Currently, there is no data on the possible development of negative manifestations when simultaneous use of the product with alcoholic beverages.
Storage
The instructions for use recommend storing the medical product at a temperature not exceeding twenty-five degrees Celsius. Storage must be carried out with the container with the drug in a vertical position. Freezing, overheating and damaging the cylinder is strictly prohibited.
The shelf life of the medication is thirty-six months.
Sales in pharmacy chains
You can purchase a medical product in a pharmacy chain without a prescription.
Analogs
In case of allergic reactions or if the medication is not effective, it is recommended to consult a medical specialist who can prescribe a replacement.
Approximate list of drug analogues:
Broncho-munal.
Broncho-vax.
Spray based on lysates of beneficial bacteria. Used as a local immunostimulating agent. The composition of the drug is unique and helps to resist the proliferation of pathogenic flora. Can be used in children from an early age and even in pregnant women after consultation with a doctor.
Dosage form
IRS 19 is an effective remedy that allows you to get rid of respiratory tract pathologies. The drug is of bacterial origin. It comes in the form of a nasal spray. The product is a liquid that can be of the following colors:
- transparent;
- colorless;
- light yellow.
The liquid has a slight specific odor. The drug is available in the form of aerosol glass containers. Their volume is 20 ml. There is a continuous valve on the cylinder. A spray nozzle is sold along with the medicine. All components of the drug are placed in cardboard packaging.
Description and composition
The main component of the product is bacterial lysates. Once in the human body, the medicine has a stimulating effect on nonspecific and specific immunity.
When the product is sprayed, an aerosol is formed. It settles on the mucous membrane of the upper respiratory tract. This leads to rapid stimulation of the activity of the human immune system. During exposure, secretory antibodies of the IgA class are formed. They do not allow pathogens to attach to the walls of the respiratory tract and continue to spread further.
Additionally, the drug increases the activity of macrophages - cells that destroy pathogenic microorganisms and absorb them.
The effect of the drug is due to its unique composition. Its main active ingredient is a bacterial lysate consisting of:
- Streptococcus pneumoniae type;
- Streptococcus pneumoniae type II;
- Streptococcus pneumoniae type III;
- Streptococcus pneumoniae type V;
- Streptococcus pneumoniae type VIII;
- Streptococcus pneumoniae type XII;
- Haemophilus influenzae type B;
- Klebsiella pneumoniae ss pneumoniae;
- Staphylococcus aureus ss aureus;
- Acinetobacter calcoaceticus;
- Moraxella catarrhalis;
- Neisseria subflava;
- Neisseria perflava;
- Streptococcus pyogenes group A;
- Streptococcus dysgalactiae group C;
- Enterococcus faecium;
- Enterococcus faecalis;
- Streptococcus group G.
The drug also contains additional substances. These include:
- sodium merthiolate;
- nerol-based flavoring (linalol, alpha-terpineol, geraniol, methyl anthranilate, limonene, geranyl acetate, linalyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol);
- purified water - up to 100 ml.
Pharmacological group
IRS 19 is an immunostimulating drug of bacterial origin.
Indications for use
for adults
IRS 19 may be prescribed in the following situations:
- restoration of local immunity is required after a person has suffered from influenza or other viral infections;
- for the prevention of chronic diseases of the bronchi and upper respiratory tract;
- as preparation for subsequent planned intervention on ENT organs and during the postoperative period;
- for the treatment of acute and chronic diseases of the bronchi and upper respiratory tract (sinusitis, rhinitis and other problems included in the category).
for children
IRS 19 is not prescribed to children who have not yet reached the age of 3 months. If the child is older than the above age, the medication is used to combat respiratory diseases.
The toxic effect of the drug on the fetus during pregnancy or during subsequent feeding has not been identified. The doctor will prescribe the drug for the treatment of acute and chronic diseases of the bronchi and upper respiratory tract, restoration of local immunity, or as preparation for surgery.
Contraindications
The medicine should not be used if a person has hypersensitivity to the components included in the drug or has autoimmune diseases.
Applications and dosages
for adults
The drug is administered into the body intranasally by aerosol administration. One dose is equal to one short press on the spray bottle.
The dosage of the drug can vary significantly depending on the goal that a person pursues when using the drug. If IRS 19 is used for the prevention of diseases of the upper respiratory tract, the drug is administered 1 dose into each nostril 2 times a day. The duration of treatment in this situation is at least two weeks. The maximum duration of the course is 21 days.
If IRS 19 is used for the treatment of acute and chronic diseases of the bronchi and upper respiratory tract, the drug is administered into each nostril one dose 2 to 5 times a day. Treatment is carried out until the infection disappears.
If the drug is used to restore immunity after a person has suffered from influenza or other viral infections, the drug is used 2 times a day. 1 dose of the product is administered into each nostril. The duration of treatment in this situation is 2 weeks.
If preparations are being made for a planned surgical intervention or recovery is carried out during the postoperative period, the drug is administered 1 dose into each nostril 2 times a day for 2 weeks. It is recommended to start the course of treatment one week before the planned operation.
for children
If the patient is a child, the dosage is similar to the parameters observed when treating an adult. An exception to the rule is the fight against acute or chronic diseases of the upper respiratory tract or bronchi. In this situation, children who have reached the age of 3 months to 3 years are prescribed one dose of the drug in each nostril. Treatment is carried out 2 times a day. The product can be used only after the nose has been freed from mucous discharge. Treatment is carried out until the symptoms of infection disappear. If the child is over 3 years old, doses are set as for an adult.
for pregnant women and during lactation
The dosage and features of use of the drug during pregnancy and lactation are determined by the doctor.
Side effects
The drug is not harmless. It can lead to a number of side effects. After using the product you may experience:
- From the digestive system: diarrhea, nausea, abdominal pain. Symptoms are usually rare and may appear early in treatment.
- Allergic reactions: or angioedema. Usually the side effect is rare.
- From the respiratory system: asthma attacks, cough. At the beginning of treatment, sinusitis may appear.
- Other side effects. Increase in body temperature to 39 degrees Celsius for no apparent reason. Typically, this effect may occur at the beginning of treatment.
Side effects are not always related to the effects of the drug. If a person notices one of the above symptoms after consuming IRS 19, they should immediately contact a specialist.
Interaction with other drugs
There were no cases of negative interaction of IRS 19 with other drugs. If a person has symptoms of a bacterial infection, antibiotics may be prescribed against the background of using the drug.
special instructions
When starting treatment with the drug, a person must be prepared for the occurrence of negative reactions. So, when the drug is used for the first time, a person may experience increased nasal discharge or sneezing. This phenomenon is usually short-term in nature. If the body’s reaction becomes severe, it is worth reducing the frequency of administration of IRS 19 or stopping the drug altogether.
In rare cases, during the start of treatment, an increase in temperature up to 39 degrees may be observed. If such a phenomenon occurs, the use of the product must be immediately discontinued. However, a person must clearly distinguish the increase in temperature caused by the use of the drug from the effect that the course of the disease gives. If the phenomenon is accompanied by malaise, it may be associated with the development of diseases of the ENT organs.
If symptoms of a bacterial infection appear, the doctor should consider prescribing antibiotics while taking IRS 19.
If the drug is prescribed to patients who suffer from bronchial asthma, an increase in attacks is possible. In this situation, it is necessary to immediately stop using the drug and not resort to its help in the future. IRS 19 does not affect the ability to drive vehicles and control potentially dangerous mechanisms.
Overdose
There were no cases of overdose with IRS 19.
Storage conditions
The drug should be stored out of the reach of children. The product must be placed strictly in a vertical position. The air temperature should not exceed 25 degrees Celsius.
The shelf life of the drug is 3 years from the date of manufacture. If the period is exceeded, use of the product is prohibited.
During storage, the drug should be placed in a place inaccessible to sunlight. It is necessary to ensure that the cylinder does not overheat above 50 degrees Celsius. The bottle must not be pierced or burned, even if there is no drug in it.
Analogs
There are no complete analogues of the drug IRS 19 on sale; there are only its substitutes according to the pharmacological group:
- Broncho-Vaxom for adults and Broncho-Vaxom for children are a Swiss preparation containing a mixture of bacterial lysates. It is available in capsules for oral administration. The dosage form for adults can be used from 12 years of age. Broncho-Vaxom for children is designed specifically for children aged 6 months to 12 years.
- refers to immunostimulating drugs. It is available in tablets and granules, from which a solution is made for oral administration. The medication is used for the treatment and prevention of infections of the ENT organs in patients older than 6 months. According to indications, the drug can be prescribed to pregnant and lactating patients when the benefit to them outweighs the potential harm to the child.
- - an immunostimulating agent used for the treatment and prevention of infectious diseases of the respiratory system. The drug contains bacterial lysate as active ingredients. This is a Swiss medicine, produced in capsules, which are approved from 12 years of age.
- P is also produced in capsules by Sandoz, Switzerland. The drug is recommended for children from 6 months to 12 years for the prevention and treatment of infectious diseases of the respiratory system.
Drug price
The cost of Irs 19 is on average 506 rubles. Prices range from 435 to 924 rubles.
Latest update of the description by the manufacturer 08.08.2007
Filterable list
Active substance:
ATX
Pharmacological group
Nosological classification (ICD-10)
3D images
Composition and release form
| Nasal spray | 100 ml |
| active substances: | |
| bacterial lysates | 43.27 ml |
| composition of bacterial lysates: | |
| Streptococcus pneumoniae type I, II, III, V, VIII, XII to | 1.11 ml |
| Staphylococcus aureus ss aureus | 9.99 ml |
| Neisseria subflava | 2.22 ml |
| Neisseria perflava | 2.22 ml |
| Klebsiella pneumoniae ss pneumoniae | 6.66 ml |
| Moraxella catarrhalis | 2.22 ml |
| Haemophilus influenzae type B | 3.33 ml |
| Acinetobacter calcoaceticus | 3.33 ml |
| Enterococcus faecium | 0.83 ml |
| Enterococcus faecalis | 0.83 ml |
| Streptococcus pyogenes group A | 1.66 ml |
| Streptococcus dysgalactiae group C | 1.66 ml |
| Streptococcus group G | 1.66 ml |
| Excipients: glycine - 4.25 g; sodium merthiolate - no more than 1.2 mg; Nerol-based flavoring (linalol, alpha-terpineol, geraniol, methyl anthranilate, limonene, geranyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol) - 12.5 mg; purified water - up to 100 ml |
in bottles of 20 ml (60 doses); 1 bottle in a box.
Description of the dosage form
Transparent, colorless, sometimes with a yellowish tint, liquid with a faint odor of Nerol-based flavoring.
Characteristic
Complex preparation from bacterial lysates.
pharmachologic effect
pharmachologic effect- increases specific and nonspecific immunity.Pharmacodynamics
IRS ® 19 increases specific and nonspecific immunity. When IRS ® 19 is sprayed, a fine aerosol is formed that covers the nasal mucosa, which leads to the rapid development of a local immune response. Specific protection is due to locally formed antibodies of the class of secretory immunoglobulins type A (IgA), which prevent the fixation and reproduction of infectious agents on the mucosa. Nonspecific immunoprotection manifests itself in an increase in the phagocytic activity of macrophages and an increase in the content of lysozyme.
Indications of the drug IRS ® 19
prevention of chronic diseases of the upper respiratory tract and bronchi;
treatment of acute and chronic diseases of the upper respiratory tract and bronchi (rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis), etc.;
restoration of local immunity after influenza and other viral infections;
preparation for planned surgical intervention on ENT organs and in the postoperative period.
Contraindications
history of hypersensitivity to the drug or its components;
autoimmune diseases.
Use during pregnancy and breastfeeding
Side effects
While taking IRS ® 19, the following side effects, both related and not related to the action of the drug, may be observed.
Skin reactions: in rare cases, hypersensitivity reactions (urticaria, angioedema) and skin erythema-like and eczema-like reactions are possible.
From the ENT and respiratory organs: rarely - asthma attacks and cough.
In rare cases, at the beginning of treatment, increased body temperature (≥39 °C) for no apparent reason, nausea, vomiting, abdominal pain, diarrhea, nasopharyngitis, sinusitis, laryngitis, bronchitis may be observed.
Isolated cases of thrombocytopenic purpura and erythema nodosum have been described.
Interaction
Cases of negative interactions with other drugs are unknown. If clinical symptoms of a bacterial infection appear, antibiotics may be prescribed while using IRS ® 19.
Directions for use and doses
Intranasally, by aerosol administration of 1 dose (1 dose = 1 short press of the spray). When spraying the drug, you need to keep the bottle in an upright position and do not throw your head back.
For prevention adults and children from 3 months of age (2-3 weeks before the expected increase in incidence) - 1 dose of the drug in each nasal passage 2 times a day for 2 weeks.
For the treatment of acute and chronic diseases of the upper respiratory tract and bronchi: adults and children over 3 years old - 1 dose of the drug in each nasal passage 2-5 times a day; children from 3 months to 3 years - 1 dose of the drug in each nasal passage 2 times a day (after preliminary release of mucous discharge). Treatment is carried out until the symptoms of infection disappear.
To restore local immunity after influenza and other respiratory viral infections: adults and children - 1 dose of the drug in each nasal passage 2 times a day for 2 weeks.
In preparation for planned surgery and in the postoperative period: adults and children - 1 dose of the drug in each nasal passage 2 times a day for 2 weeks (it is recommended to start the course of treatment 1 week before the planned surgical intervention).
At the beginning of treatment, reactions such as sneezing and increased nasal discharge may occur. As a rule, they are short-term in nature. If these reactions become severe, the frequency of administration of the drug should be reduced or discontinued.
If the drug is left for a long time without use, a drop of liquid may evaporate and the resulting crystals will clog the outlet of the nozzle. This phenomenon occurs most often when the nozzle is removed and placed in the packaging, top end down, next to the bottle, without first rinsing and drying it. If the nozzle is clogged, several presses are made in a row so that the liquid can pass under the influence of excess pressure. If this does not help, lower the nozzle into warm water for a few minutes.
Overdose
Cases of overdose are unknown.
Precautionary measures
The use of IRS 19 ® does not affect psychomotor functions associated with driving a car or operating machines and mechanisms.
special instructions
When prescribing drugs based on bacterial lysates for the purpose of immunostimulation in patients with bronchial asthma, asthma attacks may occur. In this case, it is recommended to stop treatment and not take drugs of this class in the future.
Precautions for use
Spray bottle:
Keep away from temperatures above 50 °C and from direct sunlight;
Do not puncture the bottle;
Do not burn the bottle, even if it is empty.
Manufacturer
Solvay Pharma, France.
Storage conditions for the drug IRS ® 19
At a temperature of 2-8 °C (do not freeze).Keep out of the reach of children.
Shelf life of the drug IRS ® 19
3 years.Do not use after the expiration date stated on the package.
Synonyms of nosological groups
| Category ICD-10 | Synonyms of diseases according to ICD-10 |
|---|---|
| J01 Acute sinusitis | Inflammation of the paranasal sinuses |
| Inflammatory diseases of the paranasal sinuses | |
| Purulent-inflammatory processes of the paranasal sinuses | |
| Sinus infection | |
| Combined sinusitis | |
| Exacerbation of sinusitis | |
| Acute inflammation of the paranasal sinuses | |
| Acute bacterial sinusitis | |
| Acute sinusitis in adults | |
| Subacute sinusitis | |
| Acute sinusitis | |
| Sinusitis | |
| J02.9 Acute pharyngitis, unspecified | Purulent pharyngitis |
| Lymphonodular pharyngitis | |
| Acute nasopharyngitis | |
| J03.9 Acute tonsillitis, unspecified (angina agranulocytic) | Angina |
| Sore throat, alimentary-hemorrhagic | |
| Sore throat secondary | |
| Primary tonsillitis | |
| Sore throat follicular | |
| Sore throats | |
| Bacterial tonsillitis | |
| Inflammatory diseases of the tonsils | |
| Throat infections | |
| Catarrhal sore throat | |
| Lacunar tonsillitis | |
| Acute sore throat | |
| Acute tonsillitis | |
| Tonsillitis | |
| Acute tonsillitis | |
| Tonsillar tonsillitis | |
| Follicular tonsillitis | |
| Follicular tonsillitis | |
| J04 Acute laryngitis and tracheitis | Infectious and inflammatory disease of ENT organs |
| Laryngitis | |
| Laryngitis acute | |
| Acute tracheitis | |
| Pharyngolaryngitis | |
| J06 Acute upper respiratory tract infections of multiple and unspecified localization | Bacterial infections of the upper respiratory tract |
| Bacterial respiratory infections | |
| Pain due to colds | |
| Pain in infectious and inflammatory diseases of the upper respiratory tract | |
| Viral respiratory disease | |
| Viral respiratory tract infections | |
| Inflammatory disease of the upper respiratory tract | |
| Inflammatory diseases of the upper respiratory tract | |
| Inflammatory diseases of the upper respiratory tract with difficult to separate sputum | |
| Inflammatory diseases of the respiratory tract | |
| Secondary infections with influenza | |
| Secondary infections due to colds | |
| Influenza conditions | |
| Difficulty secreting sputum in acute and chronic respiratory diseases | |
| Upper respiratory tract infections | |
| Upper respiratory tract infections | |
| Respiratory tract infections | |
| Respiratory and lung infections | |
| ENT infections | |
| Infectious and inflammatory diseases of the upper respiratory tract | |
| Infectious and inflammatory diseases of the upper respiratory tract and ENT organs | |
| Infectious and inflammatory diseases of the upper respiratory tract in adults and children | |
| Infectious and inflammatory diseases of the upper respiratory tract | |
| Infectious inflammation of the respiratory tract | |
| Respiratory tract infection | |
| Qatar of the upper respiratory tract | |
| Catarrhal inflammation of the upper respiratory tract | |
| Catarrhal disease of the upper respiratory tract | |
| Catarrhal phenomena from the upper respiratory tract | |
| Cough in diseases of the upper respiratory tract | |
| Cough with a cold | |
| Fever due to influenza | |
| ARVI | |
| acute respiratory infections | |
| Acute respiratory infection with symptoms of rhinitis | |
| Acute respiratory infection | |
| Acute infectious-inflammatory disease of the upper respiratory tract | |
| Acute cold | |
| Acute respiratory disease | |
| Acute respiratory disease of influenza nature | |
| Sore throat or nose | |
| Cold | |
| Colds | |
| Colds | |
| Respiratory infection | |
| Respiratory viral infections | |
| Respiratory diseases | |
| Respiratory infections | |
| Recurrent respiratory tract infections | |
| Seasonal colds | |
| Seasonal colds | |
| Frequent colds and viral diseases | |
| J10 Influenza caused by an identified influenza virus | Influenza A |
| Influenza B | |
| Influenza type A | |
| Flu type B | |
| J11 Influenza, virus not identified | Flu pain |
| Flu | |
| Flu in the initial stages of the disease | |
| Flu in children | |
| Influenza condition | |
| Influenza | |
| Beginning flu state | |
| Acute parainfluenza disease | |
| Parainfluenza | |
| Parainfluenza condition | |
| Influenza epidemics | |
| J30 Vasomotor and allergic rhinitis | Allergic rhinopathy |
| Allergic diseases of the upper respiratory tract | |
| Allergic respiratory diseases | |
| Allergic runny nose | |
| Allergic rhinitis | |
| Allergic rhinitis seasonal | |
| Vasomotor rhinitis | |
| Long-term allergic rhinitis | |
| Year-round allergic rhinitis | |
| Year-round allergic rhinitis | |
| Year-round or seasonal allergic rhinitis | |
| Year-round rhinitis of allergic nature | |
| Runny nose, vasomotor allergic | |
| Exacerbation of hay fever in the form of rhinoconjunctival syndrome | |
| Acute allergic rhinitis | |
| Swelling of the nasal mucosa | |
| Swelling of the nasal mucosa | |
| Swelling of the nasal mucosa | |
| Swelling of the nasal mucosa | |
| Swelling of the nasal mucosa | |
| Hay fever | |
| Persistent allergic rhinitis | |
| Rhinoconjunctivitis | |
| Rhinosinusitis | |
| Rhinosinusopathy | |
| Seasonal allergic rhinitis | |
| Seasonal allergic rhinitis | |
| Hay rhinitis | |
| Chronic allergic rhinitis | |
| J31 Chronic rhinitis, nasopharyngitis and pharyngitis | Allergic rhinosinusopathy |
| Inflammation of the nasal mucosa | |
| Infectious and inflammatory diseases of the ENT organs | |
| Year-round rhinitis | |
| Ozena | |
| Sore throat or nose | |
| Hyperplastic rhinitis | |
| Chronic rhinitis | |
| Pharyngoesophagitis | |
| Chronic bacterial rhinitis | |
| J32 Chronic sinusitis | Allergic rhinosinusopathy |
| Purulent sinusitis | |
| Catarrhal inflammation of the nasopharyngeal region | |
| Catarrhal inflammation of the paranasal sinuses | |
| Exacerbation of sinusitis | |
| Chronic sinusitis | |
| J40 Bronchitis, not specified as acute or chronic | Allergic bronchitis |
| Asthmatic bronchitis | |
| Asthmoid bronchitis | |
| Bacterial bronchitis | |
| Bronchitis | |
| Allergic bronchitis | |
| Asthmatic bronchitis | |
| Smoker's bronchitis | |
| Smokers' bronchitis | |
| Inflammation of the lower respiratory tract | |
| Bronchial disease | |
| Qatar smoker | |
| Smokers cough | |
| Disturbance of bronchial secretion | |
| Bronchial dysfunction | |
| Acute tracheobronchitis | |
| Subacute bronchitis | |
| Rhinotracheobronchitis | |
| Rhinotracheobronchitis | |
| Tracheobronchitis | |
| Chronic lung diseases | |
| J42 Chronic bronchitis, unspecified | Allergic bronchitis |
| Asthmoid bronchitis | |
| Allergic bronchitis | |
| Asthmatic bronchitis | |
| Chronic bronchitis | |
| Inflammatory disease of the respiratory tract | |
| Bronchial disease | |
| Qatar smoker | |
| Cough due to inflammatory diseases of the lungs and bronchi | |
| Exacerbation of chronic bronchitis | |
| Recurrent bronchitis | |
| Chronic bronchitis | |
| Chronic obstructive pulmonary diseases | |
| Chronical bronchitis | |
| Chronic bronchitis of smokers | |
| Chronic spastic bronchitis | |
| Z100* CLASS XXII Surgical practice | Abdominal surgery |
| Adenomectomy | |
| Amputation | |
| Angioplasty of coronary arteries | |
| Carotid angioplasty | |
| Antiseptic treatment of skin for wounds | |
| Antiseptic hand treatment | |
| Appendectomy | |
| Atherectomy | |
| Balloon coronary angioplasty | |
| Vaginal hysterectomy | |
| Corona bypass | |
| Interventions on the vagina and cervix | |
| Bladder interventions | |
| Intervention in the oral cavity | |
| Restorative and reconstructive operations | |
| Hand hygiene of medical personnel | |
| Gynecological surgery | |
| Gynecological interventions | |
| Gynecological surgeries | |
| Hypovolemic shock during surgery | |
| Disinfection of purulent wounds | |
| Disinfection of wound edges | |
| Diagnostic interventions | |
| Diagnostic procedures | |
| Diathermocoagulation of the cervix | |
| Long surgical operations | |
| Replacing fistula catheters | |
| Infection during orthopedic surgery | |
| Artificial heart valve | |
| Cystectomy | |
| Short-term outpatient surgery | |
| Short-term operations | |
| Short-term surgical procedures | |
| Cricothyroidotomy | |
| Blood loss during surgery | |
| Bleeding during surgery and in the postoperative period | |
| Culdocentesis | |
| Laser coagulation | |
| Laser coagulation | |
| Laser coagulation of the retina | |
| Laparoscopy | |
| Laparoscopy in gynecology | |
| CSF fistula | |
| Minor gynecological operations | |
| Minor surgical interventions | |
| Mastectomy and subsequent plastic surgery | |
| Mediastinotomy | |
| Microsurgical operations on the ear | |
| Mucogingival surgeries | |
| Stitching | |
| Minor surgeries | |
| Neurosurgical operation | |
| Immobilization of the eyeball in ophthalmic surgery | |
| Orchiectomy | |
| Complications after tooth extraction | |
| Pancreatectomy | |
| Pericardectomy | |
| Rehabilitation period after surgery | |
| The period of convalescence after surgical interventions | |
| Percutaneous transluminal coronary angioplasty | |
| Pleural thoracentesis | |
| Pneumonia postoperative and post-traumatic | |
| Preparing for surgical procedures | |
| Preparing for surgery | |
| Preparing the surgeon's hands before surgery | |
| Preparing the colon for surgery | |
| Postoperative aspiration pneumonia during neurosurgical and thoracic operations | |
| Postoperative nausea | |
| Postoperative bleeding | |
| Postoperative granuloma | |
| Postoperative shock | |
| Early postoperative period | |
| Myocardial revascularization | |
| Resection of the apex of the tooth root | |
| Gastric resection | |
| Bowel resection | |
| Resection of the uterus | |
| Liver resection | |
| Small bowel resection | |
| Resection of part of the stomach | |
| Reocclusion of the operated vessel | |
| Bonding tissue during surgery | |
| Removing stitches | |
| Condition after eye surgery | |
| Condition after surgery | |
| Condition after surgical interventions in the nasal cavity | |
| Condition after gastrectomy | |
| Condition after resection of the small intestine | |
| Condition after tonsillectomy | |
| Condition after removal of the duodenum | |
| Condition after phlebectomy | |
| Vascular surgery | |
| Splenectomy | |
| Sterilization of surgical instruments | |
| Sterilization of surgical instruments | |
| Sternotomy | |
| Dental operations | |
| Dental intervention on periodontal tissues | |
| Strumectomy | |
| Tonsillectomy | |
| Thoracic surgery | |
| Thoracic operations | |
| Total gastrectomy | |
| Transdermal intravascular coronary angioplasty | |
| Transurethral resection | |
| Turbinectomy | |
| Removal of a tooth | |
| Cataract removal | |
| Cyst removal | |
| Tonsil removal | |
| Removal of fibroids | |
| Removal of mobile baby teeth | |
| Removal of polyps | |
| Removing a broken tooth | |
| Removal of the uterine body | |
| Removing stitches | |
| Urethrotomy | |
| CSF duct fistula | |
| Frontoethmoidohaymorotomy | |
| Surgical infection | |
| Surgical treatment of chronic limb ulcers | |
| Surgery | |
| Surgery in the anal area | |
| Colon surgery | |
| Surgical practice | |
| Surgical procedure | |
| Surgical interventions | |
| Surgical interventions on the gastrointestinal tract | |
| Surgical interventions on the urinary tract | |
| Surgical interventions on the urinary system | |
| Surgical interventions on the genitourinary system | |
| Heart surgery | |
| Surgical procedures | |
| Surgical operations | |
| Vein surgery | |
| Surgical intervention | |
| Vascular surgery | |
| Surgical treatment of thrombosis | |
| Surgery | |
| Cholecystectomy | |
| Partial gastrectomy | |
| Transperitoneal hysterectomy | |
| Percutaneous transluminal coronary angioplasty | |
| Percutaneous transluminal angioplasty | |
| Coronary artery bypass surgery | |
| Tooth extirpation | |
| Extirpation of baby teeth | |
| Pulp extirpation | |
| Extracorporeal circulation | |
| Tooth extraction | |
| Tooth extraction | |
| Cataract extraction | |
| Electrocoagulation | |
| Endourological interventions | |
| Episiotomy | |
| Ethmoidotomy |
Country of origin
FranceProduct group
Immunomodulatory drugs and immunosuppressantsImmunostimulating drug of bacterial origin
Release forms
- Nasal spray 20 ml in an aerosol can. 1 bottle complete with nozzle and instructions for use is placed in a cardboard box.
Description of the dosage form
- Transparent, colorless or yellowish liquid with a weak specific odor.
Pharmacokinetics
The drug primarily acts in the upper respiratory tract; There are currently no data on systemic absorption of the drug.Special conditions
At the beginning of treatment, in rare cases, an increase in temperature (> 39°C) is possible. In this case, treatment should be discontinued. However, this condition should be distinguished from an increase in body temperature, accompanied by malaise, which may be associated with the development of diseases of the ENT organs. If systemic clinical signs of bacterial infection are present, systemic antibiotics should be considered. When prescribing drugs based on bacterial lysates for the purpose of immunostimulation in patients with bronchial asthma, asthma attacks may occur. In this case, it is recommended to stop treatment and not take drugs of this class in the future. Precautionary measures when using the spray bottle: - protect from heating above 50°C and from direct sunlight; - do not pierce the bottle; - do not burn the bottle, even if it is empty. Effect of the drug on the ability to drive vehicles and other mechanisms: The use of IRS® 19 does not affect the psychomotor functions associated with driving a car or operating machines and mechanisms.Compound
- Per 100 ml:
- Active substances:
- bacterial lysates 43.27 ml
- Composition of bacterial lysates:
- Streptococcus pneumoniae type I 1.11 ml
- Streptococcus pneumoniae type II 1.11 ml
- Streptococcus pneumoniae type III 1.11 ml
- Streptococcus pneumoniae type V 1.11 ml
- Streptococcus pneumoniae type VIII 1.11 ml
- Streptococcus pneumoniae type XII 1.11 mg
- Haemophilus influenzae type B 3.33 ml
- Klebsiella pneumoniae ss pneumoniae 6.66 ml
- Staphylococcus aureus ss aureus 9.99 ml
- Acinetobacter calcoaceticus 3.33 ml
- Moraxella catarrhalis 2.22 ml
- Neisseria subflava 2.22 ml
- Neisseria perflava 2.22 ml
- Streptococcus pyogenes group A 1.66 ml
- Streptococcus dysgalactiae group C 1.66 ml
- Enterococcus faecium 0.83 ml
- Enterococcus faecalis 0.83 ml
- Streptococcus group G 1.66 ml
- Excipients:
- Glycine 4.25 g
- Sodium methiolate not more than 1.2 mg
- Nerol based flavor** 12.50 mg
- Purified water up to 100 ml
- ** Nerol-based flavor composition: linalol, alpha-terpineol, geraniol, methyl anthranilate, limonene, geranyl acetate, linalyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol.
Irs-19 indications for use
- - Prevention of chronic diseases of the upper respiratory tract and bronchi
- - Treatment of acute and chronic diseases of the upper respiratory tract and bronchi, such as rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis, etc.
- - Restoration of local immunity after influenza and other viral infections.
- - Preparation for planned surgical intervention on ENT organs and in the postoperative period.
- IRS® 19 can be prescribed to both adults and children from 3 months of age.
IRS-19 contraindications
- - History of hypersensitivity to the drug or its components.
- - IRS® 19 should not be prescribed to patients with autoimmune diseases.
- Pregnancy and lactation:
- There is insufficient data on the potential for teratogenic or toxic effects on the fetus during pregnancy, therefore the use of the drug during pregnancy is not recommended.
Irs-19 side effects
- While taking IRS®19, the following side effects, both related and unrelated to the action of the drug, may occur.
- Skin reactions: in rare cases, hypersensitivity reactions (urticaria, angioedema) and erythema-like and eczema-like skin reactions are possible.
- From the ENT and respiratory organs: in rare cases - asthma attacks and cough.
- In rare cases, at the beginning of treatment the following may occur:
- fever (> 39°C) for no apparent reason, nausea, vomiting, abdominal pain, diarrhea, nasopharyngitis, sinusitis, laryngitis, bronchitis.
- Isolated cases of thrombocytopenic purpura and erythema nodosum have been described.
- If the above symptoms appear, it is recommended to consult a doctor.
Drug interactions
There are no known cases of negative interactions with other drugs. If clinical symptoms of a bacterial infection appear, antibiotics may be prescribed while continuing to use IRS® 19.Overdose
To date, no cases of overdose of IRS® 19 have been reported.Storage conditions
- keep away from children
